In glioma, inhibiting STAT3 activation by pharmacological or genetic means has been shown to reduce Olig2 levels (64), observations that may tie together lucanthone’s mechanism with the observed reduction in Olig2. The gene discussed is OLIG2; the disease is central nervous system cancer.